Phentermine cardiovascular safety

American Journal of Emergency Medicine

Volumn 27, Issue 8, 2009, Pages 1010-1013

  Rothman, Richard B ^a   Hendricks, Ed J ^b  

^a BeLite Medical Center   (United States)

^b Center for Weight Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; PHENTERMINE;

ADULT; CARDIOVASCULAR RISK; CASE REPORT; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; LETTER; OBESITY; PRIORITY JOURNAL; QT PROLONGATION;

APPETITE DEPRESSANTS; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ARREST; HUMANS; MIDDLE AGED; PHENTERMINE;

EID: 70349165358     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2009.07.014     Document Type: Letter

References (24)

1. Makaryus JN, Makaryus AN. Cardiac arrest in the setting of diet pill consumption. The American journal of emergency medicine. 2008; 26: 732 e731-733
2. Azarisman S.M., Magdi Y.A., Noorfaizan S., and Oteh M. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 357 (2007) 1873-1874
3. Hung Y.M., and Chang J.C. Weight-reducing regimen associated with polymorphic ventricular tachycardia. Am J Emerg Med 24 (2006) 714-716
4. Kokkinos J., and Levine S. Possible association of ischemic stroke with phentermine. Stroke 24 (1993) 310-313
5. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 161 (2001) 1814-1824
6. Haddock C.K., Poston W.S., Dill P.L., Foreyt J.P., and Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26 (2002) 262-273
7. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27 (2003) 1437-1446
8. Shekelle P.G., Morton S.C., Maglione M.A., et al. Pharmacological and surgical treatment of obesity. Evid Rep/Technol Assess 103 (2004) 1-172
9. Kim K.K., Cho H.J., Kang H.C., Youn B.B., and Lee K.R. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 47 (2006) 614-625
10. Haddock C.K., Poston W.S., Foreyt J.P., DiBartolomeo J.J., and Warner P.O. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. Eat Weight Disord 13 (2008) 95-101
11. Derby L.E., Myers M.W., and Jick H. Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. Br J Clin Pharmacol 47 (1999) 565-569
12. Rich S., Rubin L., Walker A.M., Schneeweiss S., and Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117 (2000) 870-874
13. Bonow R.O., Carabello B.A., Chatterjee K., et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 118 (2008) e523-e661
14. Luliano L., Micheletta F., Napoli A., and Catalano C. Myocardial infarction with normal coronary arteries: a case report and review of the literature. J Med Case Rep 3 (2009) 24
15. El Menyar A.A. Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J Postgrad Med 52 (2006) 51-56
16. Burke A.P., Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am. 2007; 91: 553-572; ix
17. Kardasz I., and De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med 261 (2007) 330-348
18. Stafford R.S., and Radley D.C. National trends in antiobesity medication use. Arch Intern Med. 163 (2003) 1046-1050
19. Hendricks E.J., Rothman R.B., and Greenway F.L. How physician obesity specialists use drugs to treat obesity. Obesity (2009) 10.1038/oby.2009.69
20. Alexander M., Rothman R.B., Baumann M.H., Endres C.J., Brasic J.R., and Wong D.F. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse. 56 (2005) 94-99
21. Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res. 12 (2004) 1821-1827
22. Nandigama R.K., Newton-Vinson P., and Edmondson D.E. Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 63 (2002) 865-869
23. Baumann M.H., Ayestas M.A., Dersch C.M., Brockington A., Rice K.C., and Rothman R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse. 36 (2000) 102-113
24. Evans S.M., Cone E.J., and Henningfield J.E. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 279 (1996) 1345-1356